Candriam S.C.A. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001537014
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2026 · 633 positions · Total reported value $22.25B · Top-10 concentration 34.5% · Updated 2026-11-13
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
Turnover: 47.4% · 21 new · 252 cut · 51 exited
Active Share (vs S&P 500): 37.1% · vs QQQ: 52.6% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -0.6% · vs SPY -2.8% · Prev Value $22.00B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -1.7% · vs SPY -3.9% · Latest Value $22.25B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2026 13F filing, Candriam S.C.A. disclosed 633 equity positions with a combined reported value of $22.25B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 34.5% of reported value. HoldingsHub classifies the profile as Large / Technology Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were NVDA ($1.56B), MSFT ($1.32B), AAPL ($1.19B). By sector, the heaviest allocations are Technology 46.8%, Health Care 21.4%. Versus the prior quarter, allocation shifted toward Technology (+2.7pp), Energy (+0.9pp) and away from Financials (-0.5pp), Utilities (-0.6pp).
Versus the prior quarter, Candriam S.C.A. opened 21 new positions, trimmed 252 and fully exited 51, a turnover rate of 47.4% of positions. The portfolio's overlap with the prior quarter was 89% of names.
The largest new positions opened in Q3 2026 were ZBIO ($17.73M), SNDK ($16.87M), GAP ($12.92M).
Of the 51 positions fully exited versus the prior quarter, the largest were SNEX ($46.10M), RARE ($33.42M), CRNX ($30.62M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2026)
- ZBIO ZENAS BIOPHARMA INC · $17.73M
- SNDK SANDISK CORP · $16.87M
- GAP GAP INC · $12.92M
- LBRX LB PHARMACEUTICALS INC · $10.95M
- BLTE BELITE BIO INC · $10.71M
- FTH Faeth Therapeutics Inc · $9.54M
- ERAS ERASCA INC · $7.24M
- BTSG BRIGHTSPRING HEALTH SVCS INC · $5.64M
Fully Exited (vs previous quarter)
- SNEX STONEX GROUP INC · prev qtr: $46.10M
- RARE ULTRAGENYX PHARMACEUTICAL IN · prev qtr: $33.42M
- CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $30.62M
- CRL CHARLES RIV LABS INTL INC · prev qtr: $23.82M
- CHE CHEMED CORP NEW · prev qtr: $19.26M
- TEVA TEVA PHARMACEUTICAL INDS LTD · prev qtr: $18.63M
- ATAI ATAIBECKLEY INC · prev qtr: $16.00M
- LEGN LEGEND BIOTECH CORP · prev qtr: $14.57M
Insider Transactions (Form 4)
Latest Candriam S.C.A. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Candriam S.C.A. is a Luxembourg-based asset management firm founded in 1989, now part of New York Life Investments, with headquarters in Strassen, Luxembourg. The firm employs a responsible investment approach integrating ESG factors across various asset classes.
Investment Approach
Responsible investment with ESG integration, combining quantitative and fundamental research, offering both active and passive investment strategies
Asset Classes
Equities, fixed income, alternatives, multi-asset solutions
Notable Facts
Part of New York Life Investments, strong focus on sustainable investing, acquired in 2018
AUM
$154.7B (SEC Form ADV regulatory figure)
Official disclosures available through SEC filings
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
6.79M | $1.56B | 6.99% | Reduce | |
| 2 |
|
2.56M | $1.32B | 5.93% | Add | |
| 3 |
|
3.55M | $1.19B | 5.33% | Reduce | |
| 4 |
|
2.33M | $803.19M | 3.61% | Reduce | |
| 5 |
|
2.37M | $592.98M | 2.67% | Reduce | |
| 6 |
|
1.64M | $578.50M | 2.60% | Reduce | |
| 7 |
|
401.21K | $465.93M | 2.09% | Hold | |
| 8 |
|
421.36K | $450.43M | 2.02% | Hold | |
| 9 |
|
684.01K | $419.98M | 1.89% | Add | |
| 10 |
|
403.58K | $293.74M | 1.32% | Add | |
| 11 |
|
837.88K | $286.54M | 1.29% | Reduce | |
| 12 |
|
620.96K | $284.31M | 1.28% | Add | |
| 13 |
|
404.54K | $274.08M | 1.23% | Add | |
| 14 |
|
676.47K | $269.75M | 1.21% | Reduce | |
| 15 |
|
679.71K | $245.13M | 1.10% | Add | |
| 16 |
|
1.82M | $244.72M | 1.10% | Add | |
| 17 |
|
713.85K | $235.36M | 1.06% | Hold | |
| 18 |
|
895.79K | $235.19M | 1.06% | Reduce | |
| 19 |
|
1.47M | $214.04M | 0.96% | Add | |
| 20 |
|
381.10K | $210.93M | 0.95% | Add | |
| 21 |
|
1.09M | $188.30M | 0.85% | Reduce | |
| 22 |
|
1.24M | $185.83M | 0.83% | Add | |
| 23 |
|
206.76K | $177.18M | 0.80% | Reduce | |
| 24 |
|
765.66K | $176.42M | 0.79% | Add | |
| 25 |
|
428.85K | $175.02M | 0.79% | Hold | |
| 26 |
|
513.20K | $170.40M | 0.77% | Reduce | |
| 27 |
|
384.90K | $153.25M | 0.69% | Add | |
| 28 |
|
352.48K | $149.12M | 0.67% | Reduce | |
| 29 |
|
1.20M | $144.81M | 0.65% | Add | |
| 30 |
|
1.88M | $142.94M | 0.64% | Reduce | |
| 31 |
|
516.64K | $137.28M | 0.62% | Add | |
| 32 |
|
681.61K | $133.35M | 0.60% | Reduce | |
| 33 |
|
173.15K | $131.77M | 0.59% | Reduce | |
| 34 |
|
425.92K | $121.61M | 0.55% | Add | |
| 35 |
|
323.07K | $119.03M | 0.54% | Add | |
| 36 |
|
440.72K | $117.11M | 0.53% | Add | |
| 37 |
|
434.20K | $115.14M | 0.52% | Reduce | |
| 38 |
|
322.48K | $114.84M | 0.52% | Add | |
| 39 |
|
1.15M | $114.20M | 0.51% | Add | |
| 40 |
|
212.93K | $111.73M | 0.50% | Add | |
| 41 |
|
289.24K | $106.23M | 0.48% | Hold | |
| 42 |
|
311.38K | $103.19M | 0.46% | Add | |
| 43 |
|
215.89K | $98.47M | 0.44% | Hold | |
| 44 |
|
336.88K | $97.10M | 0.44% | Reduce | |
| 45 |
|
412.47K | $93.51M | 0.42% | Add | |
| 46 |
|
445.69K | $91.82M | 0.41% | Reduce | |
| 47 |
|
875.84K | $89.02M | 0.40% | Reduce | |
| 48 |
|
252.30K | $88.27M | 0.40% | Reduce | |
| 49 |
|
91.92K | $87.69M | 0.39% | Reduce | |
| 50 |
|
590.17K | $86.05M | 0.39% | Reduce | |
FAQ
What did Candriam S.C.A. buy in 2026-Q3?
In its 2026-Q3 13F filing, Candriam S.C.A. reported 633 equity positions worth $22.25B in aggregate; its largest disclosed positions were NVDA ($1.56B), MSFT ($1.32B), AAPL ($1.19B).
How large is Candriam S.C.A.'s portfolio?
Candriam S.C.A. reported $22.25B of long equity holdings across 633 positions as of 2026-Q3. Top-10 holdings account for 34.5% of reported value.
What is Candriam S.C.A.'s investment style?
HoldingsHub classifies the portfolio as Large / Technology Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.